缺血性脑卒中再灌注治疗算法:以DAWN和DEFUSE-3试验为重点

I. Litvinenko, M. Odinak, A. V. Ryabtsev, S. N. Yanishevsky, S. Golokhvastov, S. Kolomentsev, R. V. Andreev, N. V. Tsygan
{"title":"缺血性脑卒中再灌注治疗算法:以DAWN和DEFUSE-3试验为重点","authors":"I. Litvinenko, M. Odinak, A. V. Ryabtsev, S. N. Yanishevsky, S. Golokhvastov, S. Kolomentsev, R. V. Andreev, N. V. Tsygan","doi":"10.18705/1607-419X-2021-27-1-29-40","DOIUrl":null,"url":null,"abstract":"The history of reperfusion treatment for ischemic stroke was officially recognized in 1996, when the use of systemic thrombolytic therapy (TLT) was authorized in the United States of America and the first clinical guidelines were published (American Heart Association (AHA) Stroke Council). The use of TLT for the treatment of ischemic stroke in the Russian Federation began in 2005–2006. The next step was the development of endovascular reperfusion techniques (2005) following the presentation of the results of the MERCI study, which evaluated the safety and efficacy of microconductors for fragmentation and destruction of blood clots. Currently, neurologists working with patients with acute cerebrovascular accidents are guided by national regulatory documents — order of the Ministry of Health of the Russian Federation dated by November 15, 2012 No. 928n “On approval of the Procedure for providing medical care to patients with acute cerebrovascular accidents” and the Protocol of reperfusion therapy acute ischemic stroke (2019), which provide basic information on the methods of diagnosis and treatment of ischemic cerebral stroke, as well as international recommendations ESO, AHA/ASA, which provide grounds for increasing therapeutic options, in particular by extending the time of the “therapeutic window”. The authors of article created the algorithm for reperfusion therapy for ischemic stroke, based on the analysis and generalization of regulatory documents, clinical guidelines and the results of DAWN and DEFUSE-3 studies.","PeriodicalId":286219,"journal":{"name":"Arterial’naya Gipertenziya","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The algorithm of reperfusion treatment of the ischemic stroke: focus on DAWN and DEFUSE-3 trials\",\"authors\":\"I. Litvinenko, M. Odinak, A. V. Ryabtsev, S. N. Yanishevsky, S. Golokhvastov, S. Kolomentsev, R. V. Andreev, N. V. Tsygan\",\"doi\":\"10.18705/1607-419X-2021-27-1-29-40\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The history of reperfusion treatment for ischemic stroke was officially recognized in 1996, when the use of systemic thrombolytic therapy (TLT) was authorized in the United States of America and the first clinical guidelines were published (American Heart Association (AHA) Stroke Council). The use of TLT for the treatment of ischemic stroke in the Russian Federation began in 2005–2006. The next step was the development of endovascular reperfusion techniques (2005) following the presentation of the results of the MERCI study, which evaluated the safety and efficacy of microconductors for fragmentation and destruction of blood clots. Currently, neurologists working with patients with acute cerebrovascular accidents are guided by national regulatory documents — order of the Ministry of Health of the Russian Federation dated by November 15, 2012 No. 928n “On approval of the Procedure for providing medical care to patients with acute cerebrovascular accidents” and the Protocol of reperfusion therapy acute ischemic stroke (2019), which provide basic information on the methods of diagnosis and treatment of ischemic cerebral stroke, as well as international recommendations ESO, AHA/ASA, which provide grounds for increasing therapeutic options, in particular by extending the time of the “therapeutic window”. The authors of article created the algorithm for reperfusion therapy for ischemic stroke, based on the analysis and generalization of regulatory documents, clinical guidelines and the results of DAWN and DEFUSE-3 studies.\",\"PeriodicalId\":286219,\"journal\":{\"name\":\"Arterial’naya Gipertenziya\",\"volume\":\"39 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arterial’naya Gipertenziya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18705/1607-419X-2021-27-1-29-40\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arterial’naya Gipertenziya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18705/1607-419X-2021-27-1-29-40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

缺血性卒中再灌注治疗的历史在1996年得到正式认可,当时美国批准使用全身溶栓治疗(TLT),并发表了第一个临床指南(美国心脏协会(AHA)卒中委员会)。俄罗斯联邦于2005-2006年开始使用TLT治疗缺血性卒中。在MERCI研究结果发表后,下一步是血管内再灌注技术的发展(2005年),该研究评估了微导体用于血液凝块破碎和破坏的安全性和有效性。目前,神经科医生在处理急性脑血管意外患者时,以国家规范性文件为指导俄罗斯联邦卫生部2012年11月15日第928n号"关于批准急性脑血管事故患者医疗程序"的命令和《急性缺血性脑卒中再灌注治疗议定书》(2019年),其中提供了缺血性脑卒中诊断和治疗方法的基本信息,以及ESO、AHA/ASA等国际建议,为增加治疗选择提供了依据;特别是通过延长“治疗窗口期”的时间。本文作者在对监管文件、临床指南以及DAWN和DEFUSE-3研究结果的分析和归纳的基础上,创建了缺血性卒中再灌注治疗算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The algorithm of reperfusion treatment of the ischemic stroke: focus on DAWN and DEFUSE-3 trials
The history of reperfusion treatment for ischemic stroke was officially recognized in 1996, when the use of systemic thrombolytic therapy (TLT) was authorized in the United States of America and the first clinical guidelines were published (American Heart Association (AHA) Stroke Council). The use of TLT for the treatment of ischemic stroke in the Russian Federation began in 2005–2006. The next step was the development of endovascular reperfusion techniques (2005) following the presentation of the results of the MERCI study, which evaluated the safety and efficacy of microconductors for fragmentation and destruction of blood clots. Currently, neurologists working with patients with acute cerebrovascular accidents are guided by national regulatory documents — order of the Ministry of Health of the Russian Federation dated by November 15, 2012 No. 928n “On approval of the Procedure for providing medical care to patients with acute cerebrovascular accidents” and the Protocol of reperfusion therapy acute ischemic stroke (2019), which provide basic information on the methods of diagnosis and treatment of ischemic cerebral stroke, as well as international recommendations ESO, AHA/ASA, which provide grounds for increasing therapeutic options, in particular by extending the time of the “therapeutic window”. The authors of article created the algorithm for reperfusion therapy for ischemic stroke, based on the analysis and generalization of regulatory documents, clinical guidelines and the results of DAWN and DEFUSE-3 studies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信